USD 299.387.512.57%

Chief Accounting Officer, VP of Fin. and Controller

Mr. Gregory F. Covino is no longer Interim Principal Financial Officer, Chief Accounting Officer, Vice President Finance of the Company., effective June 30, 2017. He currently serves as Chief Accounting Officer, Vice President Finance of Biogen Inc. Mr. Covino has served as the Companys Vice President and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporationrationration, a medical device company, as Vice President, Corporationrationrate Analysis and Control Executive since March 2010, having responsibility for the companys internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the companys international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporationrationrate Accounting from 1999 to 2002.

Age: 50 VP Since 2017

617-679-2000 http://www.biogen.com

Covino has served as our Vice President, Finance and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporationrationrationration, a medical device company, as Vice President, Corporationrationrationrate Analysis and Control since March 2010, having responsibility for the company internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporationrationrationrate Accounting from 1999 to 2002. He received his B.S. in Business Administration from Bryant University.

Management Efficiency

The company has return on total asset (ROA) of 15.29 % which means that it generated profit of $15.29 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 21.6 % meaning that it created $21.6 on every $100 dollars invested by stockholders.

The company currently holds 5.94 B in liabilities with Debt to Equity (D/E) ratio of 47.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Biogen Inc has Current Ratio of 2.29 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 7300 people.Biogen Inc (BIIB) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 7,300 people. Biogen is listed under Pharmaceutical Products category by Fama And French industry classification.